FDA approves Verona Pharma’s Ohtuvayre for COPD treatment
Ohtuvayre is claimed to be the first inhaled medication with a unique mechanism of action for COPD maintenance therapy in more than two decades. A dual inhibitor of
Signet Therapeutics has received approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for sigx1094, a potential treatment for diffuse gastric cancer (DGC).
New investors Mubadala Capital and Exor Ventures spearheaded this oversubscribed round. The Series B extension also saw participation from Qatar Investment Authority, alongside current stakeholders including Abingworth and